Table 3 Clinical characteristics of PBB in the western countries
| Author | Pritchard MG [13] | Wurzel DF [14] | Narang R [15] | Chang AB [16] | Kompare M [17] | Donnelly D [18] | Marchant JM [1] |
|---|---|---|---|---|---|---|---|
| Year | 2015 | 2014 | 2014 | 2012 | 2012 | 2007 | 2006 |
| Research | R | P | R | P | R | R | P |
| Number | 44 | 104 | 50 | 50 | 70 | 81 | 43 |
| M(F) | – | 72 (32) | – | 36 (14) | 50 (20) | 40 (41) | – |
| Age | 2.7y (1.5–4.0) | 19 m (12-30 m) | 2.9y (1.7–4.4) | 4.5y | 3 m | 3.9y (5 m-14y) | 2.6y |
| Course | 11 m (9–14.7 m) | 28w (6-57w) | 11 m (8-14 m) | >4w | 1-60 m 5 m | >1 m | >3w |
| Antibiotic used | – | – | – | – | – | 9 | – |
| Bronchoscopy | 44 | 104 | 50 | 50 | 70 | 19 | 43 |
| Pathogen | |||||||
| Hi | 27 (61.3%) | 75 (72.1%) | 25 (50%) | 5 (10%) | 39 (55%) | 65 (80%) | 20 (46.5%) |
| Mcat | 22 (50%) | 45 (43.3%) | 14 (28%) | 4 (8%) | 41 (58.6%) | – | 11 (25.5%) |
| Spn | 10 (22.7%) | 41 (39.4%) | 8 (16%) | 19 (38%) | 26 (37.1) | 30 (37%) | 15 (34.9%) |
| Sa | 8 (18.1%) | – | 11 (22%) | 4 (8%) | – | – | – |
| Adv | – | 22 (21.1%) | – | – | – | – | 2 (4.6%) |
| RSV | – | 5 (4.8%) | – | – | – | – | – |
| PIV | – | – | – | – | – | – | 1 (2.3%) |
| Comorbidities | |||||||
| Wheeze | – | 63 (60.5%) | – | 30 (60%) | – | 39 (48.1%) | – |
| Sinusitis | – | – | – | 14 (28%) | – | – | – |
| Airway stenosis | – | – | – | 6 (12%) | – | – | – |
| Tracheobronchial malacia | – | 71 (68.2%) | – | 5 (10%) | 52 (74.2%) | – | – |
| Treatment | |||||||
| Antibiotics | Amo /Cla | Amo | Amo /Cla | Amo /Cep /Azi | Amo | Amo | Amo |
| Duration | 6-8w | 2w | 6w | 2-4w | 2-4w | 4-6w | 2w |
| Follow-up | 1-4y | – | – | 1y | – | 1y | |
| Effects | – | ||||||
| Remission | – | – | – | – | – | 52 | – |
| Improve | 33 | 104 | – | 50 | 61 | – | 43 |
| Relapse | 25 | – | – | – | 43 | – | – |
| Complication | – | – | – | – | – | – | – |